TCIM
CTIC

TIAA CREF Investment Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

TIAA CREF Investment Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$106K Buy
109,634
+3,966
+4% +$4.18K ﹤0.01% 2955
2018
Q4 		$78K Sell
105,668
-3,390
-3% -$5.57K ﹤0.01% 2980
2018
Q3 		$236K Sell
109,058
-4,415
-4% -$10.9K ﹤0.01% 2941
2018
Q2 		$565K Buy
+113,473
New +$497K ﹤0.01% 2736
2016
Q1 		– Sell
-71,211
Closed -$876K – 3164
2015
Q4 		$876K Sell
71,211
-8,157
-10% -$109K ﹤0.01% 2656
2015
Q3 		$1.16M Hold
79,368
– – ﹤0.01% 2483
2015
Q2 		$1.55M Buy
79,368
+13,059
+20% +$252K ﹤0.01% 2464
2015
Q1 		$1.2M Buy
66,309
+18,793
+40% +$423K ﹤0.01% 2517
2014
Q4 		$1.12M Sell
47,516
-1,446
-3% -$33.4K ﹤0.01% 2587
2014
Q3 		$1.19M Sell
48,962
-5,714
-10% -$149K ﹤0.01% 2537
2014
Q2 		$1.54M Buy
54,676
+1,369
+3% +$41.1K ﹤0.01% 2456
2014
Q1 		$1.81M Sell
53,307
-1,167
-2% -$39.9K ﹤0.01% 2294
2013
Q4 		$1.05M Buy
54,474
+6,479
+13% +$118K ﹤0.01% 2650
2013
Q3 		$787K Sell
47,995
-10,143
-17% -$118K ﹤0.01% 2752
2013
Q2 		$610K Buy
+58,138
New +$681K ﹤0.01% 2872

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's CTIC Position: Q1 2019 in Review

TIAA CREF Investment Management increased its CTI BioPharma Corp. (DE) Common Stock (CTIC) stake by 3.8% in Q1 2019, buying an estimated $4.18K and bringing the position to 109,634 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #2955.

TIAA CREF Investment Management first reported a position in CTIC in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.81M in Q1 2014. 67 funds tracked by Wall St. Rank hold CTIC as of Q1 2019.

  • TIAA CREF Investment Management held 109,634 shares of CTI BioPharma Corp. (DE) Common Stock worth $106K as of Q1 2019.
  • TIAA CREF Investment Management bought 3,966 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2019, an estimated $4.18K.
  • CTI BioPharma Corp. (DE) Common Stock made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2955 holding.
  • TIAA CREF Investment Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and has held it in 15 quarters since.
  • TIAA CREF Investment Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.81M in Q1 2014.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.